Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

This study is testing a combination of three drugs — durvalumab (an immunotherapy), tremelimumab (another immune-boosting drug), and lenvatinib (a targeted drug that slows cancer growth) — as a first-line treatment for people with liver cancer (hepatocellular carcinoma or HCC) that cannot be surgically removed. **You may be eligible if...** - You have been diagnosed with liver cancer confirmed by tissue biopsy or imaging - You have not received prior systemic (body-wide) treatment for unresectable HCC - Your liver function is relatively preserved (Child-Pugh class A, which means compensated liver disease) - You are in good general health (ECOG 0–1) and have at least one measurable tumor **You may NOT be eligible if...** - You have significant unresolved side effects from prior cancer treatment - You have had a recent episode of mental confusion related to liver disease (hepatic encephalopathy), clinically significant fluid buildup in the abdomen (ascites), or a blood clot blocking the main portal vein - You have active or recent gastrointestinal bleeding - You have uncontrolled high blood pressure or are co-infected with both hepatitis B and C Talk to your doctor to see if this trial is right for you.